Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 1
1966 1
1967 1
1968 2
1970 1
1971 1
1974 1
1975 2
1976 2
1977 1
1978 1
1979 1
1980 4
1981 4
1982 5
1983 3
1984 1
1985 5
1986 2
1987 4
1988 5
1989 4
1990 7
1991 5
1992 4
1993 7
1994 10
1995 5
1996 10
1997 4
1998 6
1999 12
2000 10
2001 11
2002 10
2003 16
2004 8
2005 6
2006 15
2007 22
2008 20
2009 18
2010 14
2011 13
2012 17
2013 23
2014 32
2015 37
2016 38
2017 35
2018 28
2019 33
2020 38
2021 42
2022 27
2023 31
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

589 results

Results by year

Filters applied: . Clear all
Proximity search should include two or more words. Proximity operator ignored :~0
Page 1
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries.
Kwo PY, Cohen SM, Lim JK. Kwo PY, et al. Am J Gastroenterol. 2017 Jan;112(1):18-35. doi: 10.1038/ajg.2016.517. Epub 2016 Dec 20. Am J Gastroenterol. 2017. PMID: 27995906
The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cholestasis. Multiple studies have demonstrated that the presence of an elevated ALT has been associated with increased liver-related morta …
The majority of bilirubin circulates as unconjugated bilirubin and an elevated conjugated bilirubin implies hepatocellular disease or cho …
Neonatal Cholestasis: Updates on Diagnostics, Therapeutics, and Prevention.
Feldman AG, Sokol RJ. Feldman AG, et al. Neoreviews. 2021 Dec 1;22(12):e819-e836. doi: 10.1542/neo.22-12-e819. Neoreviews. 2021. PMID: 34850148 Free PMC article. Review.
Advances have also been made in our understanding of risk factors for parenteral nutrition-associated cholestasis/liver disease. New lipid emulsion formulations, coupled with preventive measures to decrease central line-associated bloodstream infections, have resulted in l …
Advances have also been made in our understanding of risk factors for parenteral nutrition-associated cholestasis/liver disease. New …
Hepatitis A: clinical manifestations and management.
Jeong SH, Lee HS. Jeong SH, et al. Intervirology. 2010;53(1):15-9. doi: 10.1159/000252779. Epub 2010 Jan 5. Intervirology. 2010. PMID: 20068336 Free article. Review.
Atypical manifestations include relapsing hepatitis and prolonged cholestasis, and complicated cases with acute kidney injury have been reported. Extrahepatic manifestations, such as autoimmune hemolytic anemia, aplastic anemia, pure red cell aplasia, pleural or pericardia …
Atypical manifestations include relapsing hepatitis and prolonged cholestasis, and complicated cases with acute kidney injury have be …
EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis.
European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, et al. J Hepatol. 2017 Jul;67(1):145-172. doi: 10.1016/j.jhep.2017.03.022. Epub 2017 Apr 18. J Hepatol. 2017. PMID: 28427765
Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice g …
Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies …
New Treatment Paradigms in Primary Biliary Cholangitis.
Levy C, Manns M, Hirschfield G. Levy C, et al. Clin Gastroenterol Hepatol. 2023 Jul;21(8):2076-2087. doi: 10.1016/j.cgh.2023.02.005. Epub 2023 Feb 19. Clin Gastroenterol Hepatol. 2023. PMID: 36809835 Free article. Review.
For those where liver fibrosis is the target, NOX inhibition is being evaluated. Earlier stage therapies in development include therapy to impact immunoregulation in patients, as well other approaches to treating pruritus (eg, antagonists of MrgprX4). Collectively t …
For those where liver fibrosis is the target, NOX inhibition is being evaluated. Earlier stage therapies in development include th …
Alagille syndrome: pathogenesis, diagnosis and management.
Turnpenny PD, Ellard S. Turnpenny PD, et al. Eur J Hum Genet. 2012 Mar;20(3):251-7. doi: 10.1038/ejhg.2011.181. Epub 2011 Sep 21. Eur J Hum Genet. 2012. PMID: 21934706 Free PMC article. Review.
Alagille syndrome (ALGS), also known as arteriohepatic dysplasia, is a multisystem disorder due to defects in components of the Notch signalling pathway, most commonly due to mutation in JAG1 (ALGS type 1), but in a small proportion of cases mutation in NOTCH2 (ALGS type 2). The …
Alagille syndrome (ALGS), also known as arteriohepatic dysplasia, is a multisystem disorder due to defects in components of the Notch signal …
Recent developments in diagnostics and treatment of neonatal cholestasis.
Feldman AG, Sokol RJ. Feldman AG, et al. Semin Pediatr Surg. 2020 Aug;29(4):150945. doi: 10.1016/j.sempedsurg.2020.150945. Epub 2020 Jul 23. Semin Pediatr Surg. 2020. PMID: 32861449 Free PMC article. Review.
Current therapies focus on promoting bile flow, reducing pruritus, ensuring optimal nutrition, and monitoring for complications, without addressing the underlying cause of cholestasis in most instances. Our improved understanding of bile formation and the enterohepa …
Current therapies focus on promoting bile flow, reducing pruritus, ensuring optimal nutrition, and monitoring for complications, with …
Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases.
Chen HL, Wu SH, Hsu SH, Liou BY, Chen HL, Chang MH. Chen HL, et al. J Biomed Sci. 2018 Oct 26;25(1):75. doi: 10.1186/s12929-018-0475-8. J Biomed Sci. 2018. PMID: 30367658 Free PMC article. Review.
Accumulation of excessive bile acids and aberrant metabolites results in hepatocellular injury and biliary cirrhosis. Progressive familial intrahepatic cholestasis (PFIC) is the prototype of genetic liver diseases manifesting jaundice in early childhood, progressive liver …
Accumulation of excessive bile acids and aberrant metabolites results in hepatocellular injury and biliary cirrhosis. Progressive familial i …
Neonatal diagnosis of biliary atresia: a practical review and update.
Brahee DD, Lampl BS. Brahee DD, et al. Pediatr Radiol. 2022 Apr;52(4):685-692. doi: 10.1007/s00247-021-05148-y. Epub 2021 Jul 31. Pediatr Radiol. 2022. PMID: 34331566 Review.
Biliary atresia is challenging to diagnose because many of the clinical and imaging features of this condition overlap with those of other causes of cholestasis in newborns. When jaundice persists beyond 2 weeks of age, the neonate should be evaluated for cholestasis …
Biliary atresia is challenging to diagnose because many of the clinical and imaging features of this condition overlap with those of other c …
Primary biliary cholangitis: pathogenesis and therapeutic opportunities.
Gulamhusein AF, Hirschfield GM. Gulamhusein AF, et al. Nat Rev Gastroenterol Hepatol. 2020 Feb;17(2):93-110. doi: 10.1038/s41575-019-0226-7. Epub 2019 Dec 9. Nat Rev Gastroenterol Hepatol. 2020. PMID: 31819247 Review.
Substantial progress has been made in patient risk stratification with the goal of personalized care, including early adoption of next-generation therapy with licensed use of obeticholic acid or off-label fibrate derivatives for those with insufficient benefit from …
Substantial progress has been made in patient risk stratification with the goal of personalized care, including early adoption of nex …
589 results